Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/106167A FORMULATION FOR THE PREVENTION AND TREATMENT OF MASTITIS IN DAIRY ANIMALS, IN PARTICULAR COWS
WO 28.05.2020
Int.Class A61K 33/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
38Silver; Compounds thereof
Appl.No PCT/PL2019/050035 Applicant NANOBIOSOL SP. Z O.O. Inventor CIERPISZ, Jarosław
The subject of the invention is a formulation for the prevention and treatment of mastitis in dairy animals, notably cows, characterized in that it consists of silver nanoparticles having a particle size below 10 nm and from 5 to 25% of glycerol or from 10 to 30% of DMSO or a mixture of glycerol and DMSO used in a ratio of 1:1 in an amount of 5 to 20% vol.
2.WO/2020/106976COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
WO 28.05.2020
Int.Class A61K 31/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
Appl.No PCT/US2019/062644 Applicant CERTEGO THERAPEUTICS Inventor OSTEN, Pavel
This disclosure reports on the discovery that low dose lithium can act in synergy with gaboxadol to enhance lithium's action on brain signaling activity. This combination of lithium and gaboxadol may greatly reduce the amount of lithium needed to treat many debilitating psychiatric disorders, such as bipolar disorder, depression, treatment resistant depression and suicidality, while reducing the often-serious side effects associated with high dose and chronic lithium treatment, especially ephrotoxicity, nephrogenic diabetes insipidus andchronic kidney disease. Coadministration of gaboxadol and lithium may also be useful for the treatment of refractory bipolar disorder, i.e. bipolar disorder which cannot be treated appropriately by administration of lithium alone. Gaboxadol may also prove useful as add-on therapy for the augmentation of the response to lithium in patients that do not respond to conventional lithium monotherapy.
3.WO/2020/104855CARBOCYSTEINE AND ZINC TABLET
WO 28.05.2020
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
Appl.No PCT/IB2019/050062 Applicant NOVEX SCIENCE PTE LIMITED Inventor HERRERA, Ellen
The present invention relates to a carbocysteine and zinc tablet which contains not less than 500 mg of carbocysteine and 3-10 mg of elemental zinc wherein the carbocysteine is present from about 40% w/w to about 60% w/w of the tablet weight. The subject carbocysteine and zinc tablet is characterized by fast disintegration, low friability, and good manufacturability.
4.WO/2020/106513BIOACTIVE PHOSPHATE GLASSES
WO 28.05.2020
Int.Class C03C 3/064
CCHEMISTRY; METALLURGY
03GLASS; MINERAL OR SLAG WOOL
CCHEMICAL COMPOSITION OF GLASSES, GLAZES, OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
3Glass compositions
04containing silica
062with less than 40% silica by weight
064containing boron
Appl.No PCT/US2019/061077 Applicant CORNING INCORPORATED Inventor MA, Lina
The disclosure relates to bioactive glasses for use in biomedical applications. In particular, the glasses described herein are phosphate glasses that show fast filling rates of dentin tubules and have advantageous release rates of metal ions, which provide advantages in antibacterial applications and wound healing.
5.WO/2020/104631HEALING COMPOSITION COMPRISING ELECTROLYZED WATER
WO 28.05.2020
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No PCT/EP2019/082164 Applicant WATERDIAM FRANCE SAS Inventor PUPUNAT, Laurent
The present invention relates to a composition comprising electrolyzed water for use as a healing medicament. It also relates to the use of such a composition for the treatment of skin conditions.
6.WO/2020/104911COMBINATION OF CHEMOTHERAPY WITH RECOMBINANT S. ROLFSII LECTIN
WO 28.05.2020
Int.Class A61K 31/337
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
337having four-membered rings, e.g. taxol
Appl.No PCT/IB2019/059873 Applicant UNICHEM LABORATORIES LTD Inventor SATHE, Dhananjay
The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 in combination with other therapeutic agents, wherein the other therapeutic agents are anti-cancer agents. The combinations are highly synergistic and efficacious against several cancers.
7.WO/2020/105701NOVEL POLYMER-ACTIVE DRUG CONJUGATE AND USE THEREOF
WO 28.05.2020
Int.Class A61K 31/704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
Appl.No PCT/JP2019/045604 Applicant KYOTO PHARMACEUTICAL INDUSTRIES, LTD. Inventor TAKEDA, Shigemitsu
The present invention addresses the problem of providing a polymer-anticancer agent-nitric monoxide-releasing compound conjugate that, once administered intravitally, circulates continuously through the whole body and moves to a tumor tissue and accumulates there more efficiently than conventional polymer-anticancer agent conjugates, and that remains there for an extended period of time to release the anticancer agent in the low-pH environment around the tumor, thereby demonstrating excellent antitumor activity with fewer adverse effects. The present invention can provide a polymer compound, or a pharmaceutically-accepted salt thereof, that demonstrates excellent anti-cancer activity with few adverse effect, and that comprises: a constituent unit (1) represented by formula (1) [symbols in the formula are as defined in the specification]; a constituent unit (2) represented by formula (2) [symbols in the formula are as defined in the specification]; and a constituent unit (3) derived from N-(2-hydroxypropyl) methacrylamide.
8.WO/2020/106051PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, COMPRISING BOTH STREPTONIGRIN AND ANTICANCER AGENT
WO 28.05.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No PCT/KR2019/015908 Applicant MD BIOLAB CO., LTD. Inventor KIM, Soo Youl
The present invention relates to a pharmaceutical composition or an anticancer adjuvant for use in prevention or treating cancer, the composition or adjuvant comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. In addition, the present invention relates to a method for prevention or treatment of cancer, the method comprising a step of administering to a patient a pharmaceutical composition comprising both of: streptonigrin; and at least one additional anticancer agent selected from the group consisting of bortezomib, rapamycin, and gemcitabine. Therefore, the composition comprising all of streptonigrin and other anticancer agents according to the present invention has the excellent effect of inhibiting the growth of cancer cells, particularly, breast cancer cells and as such, can be effectively used in a cancer prevention or treatment composition or a cancer prevention or treatment method using same.
9.WO/2020/104630TREATMENT OF SKIN DISORDERS BASED ON ELECTROLYSED WATER
WO 28.05.2020
Int.Class C02F 1/461
CCHEMISTRY; METALLURGY
02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
1Treatment of water, waste water, or sewage
46by electrochemical methods
461by electrolysis
Appl.No PCT/EP2019/082163 Applicant WATERDIAM FRANCE SAS Inventor GINTER, Anthony
The present invention relates to a method for obtaining electrolysed water comprising the following steps: - Providing running or spring water, optionally comprising sodium chloride (NaCl) at a concentration of 0.5 to 2g/L - Electrolysing this water by means of an electrolysis module comprising at least one boron-doped diamond electrode attached to a silicon substrate in which the concentration of boron is between 200 ppm (3x1019 B atoms/cm3) and 1500 ppm (2x1020 B atoms/cm3), the electric current density during the electrolysis process being between 15 and 500 mAh/L water, more preferably between 40 and 250 mAh/L water, and more preferably still between 50 and 200 mAh/L, and the electrolysis period being less than or equal to 60 minutes. The invention also concerns a water obtained according to this method for treating skin disorders and a composition containing such a water and a device for treating skin disorders comprising a vessel containing a water obtained according to the inventive method.
10.WO/2020/106050PHARMACEUTICAL COMPOSITION COMPRISING BOTH STREPTONIGRIN AND ANTI-CANCER AGENT FOR PREVENTING OR TREATING CANCER
WO 28.05.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No PCT/KR2019/015907 Applicant MD BIOLAB CO., LTD. Inventor KIM, Soo Youl
The present invention relates to a pharmaceutical composition or an adjuvant anti-cancer agent for preventing or treating cancer comprising both streptonigrin and and one or more anti-cancer agents selected from the group consisting of cisplatin, gemcitabine, and paclitaxel. Additionally, the present invention relates to a method for preventing or treating cancer comprising the step for administering, to a patient, the pharmaceutical composition comprising both streptonigrin and one or more anti-cancer agents selected from the group consisting of cisplatin, gemcitabine, and paclitaxel. Therefore, the composition according to the present invention comprising both streptonigrin and other anti-cancer agents is highly effective in inhibiting cancer cell growth, especially the growth of ovarian cancer cells, and thus can be effectively used in a composition or method using the composition for preventing or treating cancer.